Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

744.50 +1.15 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
Check Out What Whales Are Doing With REGN
Via Benzinga
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025. 
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
28 Analysts Have This To Say About Regeneron Pharmaceuticals
Via Benzinga
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
Via Benzinga
2 Top Growth Stocks to Buy on the Dip
Their recent issues are nothing to fret over for investors focused on the long game. 
Via The Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. 
Via Benzinga
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Regeneron Earnings Top Views For Biotech Giant
Shares of the biotech giant have been in a sharp slide. 
Via Investor's Business Daily
3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
Check out these three stocks with financial metrics showing recession resistance and underlying business dynamics to back them up. 
Via MarketBeat
Topics Bankruptcy Bonds Economy
Exposures Debt Markets Economy Financial
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today. 
Via The Motley Fool
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market. 
Via Benzinga
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance. 
Via Benzinga
Regeneron Reports Third Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients. 
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
One of these players has split its stock in the past. The other one hasn't. 
Via The Motley Fool
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.